

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT

This is a voluntary announcement made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on January 12, 2023, the Company entered into a non-legally binding strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with Shaanxi Pharmaceutical Holding Group Co., Ltd. (陝西醫藥控股集團有限責任公司) (“**Shaanxi Pharmaceutical**”) and Shaanxi Pharmaceutical Holding Group Paion Pharmaceutical Co., Ltd. (陝西醫藥控股集團派昂醫藥有限責任公司) (“**Paion**”).

Shaanxi Pharmaceutical is a sizeable and leading Chinese state-owned pharmaceutical company operating in various pharmaceutical businesses. Paion, a major subsidiary of Shaanxi Pharmaceutical, is a pharmaceutical distribution company with diversified business formats, wide coverage and large distribution size.

Pursuant to the Strategic Cooperation Agreement, the parties hope to establish long-term strategic cooperation in the fields of healthcare digitalisation and pharmaceutical supply chain in the Mainland China through business collaboration and equity investments. In terms of business collaboration, the parties plan to strategically cooperate in the areas of pharmaceutical products sales and procurement, warehousing and supply chain coordination, GPO (group purchasing organization) for private hospitals and pharmacy SaaS solution. To facilitate and deepen such strategic cooperation, the parties intend to make mutual investments whereby Shaanxi Pharmaceutical (or its affiliate) intends to invest in the Company’s in-hospital solution segment and the Company (or its affiliate) intends to invest in Paion.

The Board considers that the Strategic Cooperation Agreement provides a valuable opportunity to the parties to leverage their respective resources and expertise and create mutual benefits and synergy to each other. Therefore, the Board is of the view that entering into the Strategic Cooperation Agreement is in the interest of the Company and its shareholders as a whole.

To the best of the knowledge, information and belief of the Board having made all reasonable enquiries, Shaanxi Pharmaceutical and Paion are each a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Further announcement(s) in relation to the possible cooperation will be made by the Company as and when appropriate in compliance with the Listing Rules. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, January 12, 2023

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*